培美曲塞二钠(PMD)对比多西紫杉醇单药二线治疗晚期非小细胞肺癌的临床观察

PMD Comparing Docetaxel Single-agent Second-line Treatment of Advanced n Non-small Cell Lung Cancer Clinical Observation

目的探讨培美曲塞二钠(pemetrexed disodium,PMD)对比多西他赛(DOC)单药二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法选择经病理学或细胞学确诊一线治疗失败的NSCLC患者69例,分为2组,PMD组24例患者采用单药PMD治疗,DOC组采用单药DOC治疗,化疗2个周期后评价疗效及观察毒副反应。结果 2组的有效率、疾病控制率、中位生存期、1年生存率比较无统计学意义(P>0.05);PMD组的血液学毒性(粒细胞减少)明显低于DOC组(P>0.05),其他消化道反应、乏力、脱发等无差异(P>0.05)。结论 PMD对比DOC单药二线治疗晚期NSCLC临床疗效相似,PMD的血液学毒性反应相对明显降低,故更适于治疗二线晚期NSCLC患者。

Objective To investigate the effect of pemetrexed two sodium （pemetrexed disodium, PMD） compared with docetaxel （DOC） alone in the second-line treatment of advanced non small cell lung cancer （NSCLC） the efficacy and side effect. Methods Pathology or cytology failed first-line treatment of 69 cases of NSCLC patients, divided into 2 groups, 24 cases in PMD group using a single drug treatment of PMD, and group DOC with single drug DOC treatment, to observe the therapeutic effect and toxicity evaluation after 2 cycles of chemotherapy. Results The efifciency of the 2 groups, disease control rate, median survival time, 1 years survival rate showed no statistical signiifcance （P〉0.05）;PMD group of hematological toxicities （neutropenia） was signiifcantly lower than that in DOC group （P〉0.05）, there was no difference in other gastrointestinal reaction, fatigue, alopecia （P〉0.05）. Conclusion The curative effect of PMD compared with DOC alone in the second-line treatment of advanced NSCLC, PMD hematological toxicity relative reduced obviously. It is more suitable for second-line therapy for advanced NSCLC patients.